References
No excuse for leaving infants and children in pain. Drug Ther Perspect 1995 Dec 11; 6(12): 5–8
Jacqz-Aigrain E, Burtin P. Clinical pharmacokinetics of sedatives in neonates. Clin Pharmacokinetic 1996 Dec; 31(6): 423–43
Jacqz-Aigrain E, Daoud P, Burtin P, et al. Placebo-controlled trial of midazolam sedation in mechanically ventilated new-born infants. Lancet 1994; 344: 646–50
British National Formulary No. 33. London: The Pharmaceutical Press, 1997 Mar: 157–8, 529
1997 Physicians GenRx. St Louis, Missouri: Mosby-Year Book, Inc., 1997: 11–645, 11-1296, 11-1439
Maloley PA, Gal P, Mize R, et al. Lorazepam dosing in neonates: application of objective sedation scores [letter]. DICP 1990; 24: 326–7
Cronin CM. Neurotoxicity of lorazepam in a premature infant. Pediatrics 1992; 89: 1129
Reiter PD, Stiles AD. Lorazepam toxicity in a premature infant. Ann Pharmacother 1993; 27: 727–9
Van den Anker JN, Sauer PJJ. The use of midazolam in the preterm neonate [letter]. Eur J Pediatr 1992; 151: 152
Burtin P, Daoud P, Jacqz-Aigrain E, et al. Hypotension with midazolam and fentanyl in the newborn. Lancet 1991; 337: 1545–6
Rights and permissions
About this article
Cite this article
Midazolam: the choice for continuous sedation in neonates. Drugs Ther. Perspect 10, 12–14 (1997). https://doi.org/10.2165/00042310-199710100-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199710100-00004